DaVita Clinical Research (DCR), a subsidiary of DaVita Inc., has begun enrollment on two clinical research trials to study how COVID-19 affects people with end stage kidney disease (ESKD) who are...
DaVita Inc. (NYSE: DVA) ("DaVita"), a health care provider focused on transforming care delivery to improve quality of life for patients globally and one of the largest providers of kidney care...
DaVita has expanded a tuition and support program for its clinical teammates to help them earn an associate's degree in nursing. The program, named Bridge to Your Dreams, includes comprehensive...
DaVita Inc. (NYSE: DVA) announced today that its Board of Directors appointed a new independent director, Ms. Paula A. Price, to join the Board, effective September 1, 2020. "We are very excited...
DaVita Inc. (NYSE: DVA) ("DaVita") announced today the pricing of its previously announced private offering of $1.5 billion aggregate principal amount of senior notes due 2031 (the "2031 notes")....